Oaktree Acquisition Corp. III Life Sciences
OACC
$10.64
-$0.01-0.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 255.50K | 225.60K | 269.80K | 444.80K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 255.50K | 225.60K | 269.80K | 444.80K | |
| Operating Income | -255.50K | -225.60K | -269.80K | -444.80K | |
| Income Before Tax | 1.79M | 1.97M | 1.87M | 1.66M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 1.79M | 1.97M | 1.87M | 1.66M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 1.79M | 1.97M | 1.87M | 1.66M | |
| EBIT | -255.50K | -225.60K | -269.80K | -444.80K | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 0.07 | 0.08 | 0.08 | 0.07 | |
| Normalized Basic EPS | 0.05 | 0.05 | 0.05 | 0.04 | |
| EPS Diluted | 0.07 | 0.08 | 0.08 | 0.07 | |
| Normalized Diluted EPS | 0.05 | 0.05 | 0.05 | 0.04 | |
| Average Basic Shares Outstanding | 24.58M | 24.58M | 24.58M | 24.58M | |
| Average Diluted Shares Outstanding | 24.58M | 24.58M | 24.58M | 24.58M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |